Background: Benign prostatic hyperplasia and prostate cancer (PCA) alter the normal growth patterns of zonal anatomy with changes of prostate volume (PV). Chronic inflammatory infiltrates (CII) type IV are the most common non-cancer diagnosis of the prostate after biopsy. Objective: To evaluate associations of both PV index (PVI), i.e. the ratio of transitional zone volume (TZV) to peripheral zone volume (PZV), and CII with PCA in patients undergoing biopsy. Subjects and Methods: Between January 2007 and December 2008, 268 consecutive patients who underwent prostate biopsy were retrospectively evaluated. PV and TZV were measured by transrectal ultrasound. PZV was computed by subtracting the PV from the TZV. CII were evaluated according to standard criteria. Significant associations of PVI and the presence of CII (CII+) with PCA risk were assessed by statistical methods. Results and Limitations: We evaluated 251 patients after excluding cases with painful rectal examinations, prostate-specific antigen (PSA) >20 μg/ml and metastases. The PCA detection rate was 41.1%. PVI was a negative independent predictor of PCA. A PVI ≤1.0 was directly [odds ratio (OR) = 2.36] associated with PCA, which was detected more frequently in patients with a PVI ≤1.0 (29.1%) than in those with a PVI >1.0 (11.9%). CII+ was inversely (OR = 0.57) and independently associated with PCA, which was detected less frequently in cases with CII (9.9%) than in those without CII (21.1%). Potential study limitations might relate to the fact that PV was not measured by prostatectomy specimens and there was PSA confounding for CII and PCA. Conclusions: Low values of PVI are directly associated with risk of PCA, which was almost 2.5 times higher in patients with a PVI ≤1.0. The PVI might be an effective parameter for clustering patients at risk of PCA. CII+ was inversely associated with risk of PCA and decreased the probability of detecting PCA by 43%. The role of the PVI and CII in PCA carcinogenesis needs further research.

1.
Selman A: The McNeal prostate: a review. Urology 2011;78:1224-1228.
2.
Coussens LM, Werb Z: Inflammation and cancer. Nature 2002;420:860-867.
3.
Mantovani A, Allavena P, Sica A, Balkwill F: Cancer related inflammation. Nature 2008;464:436-444.
4.
Welson WG, de Marzo AM, Isaacs WB: Prostate cancer. N Engl J Med 2003;349:366-381.
5.
Blumenfeld W, Tucci S, Narayan P: Incidental lymphocytic prostatitis. Selective involvement with nonmalignant glands. Am J Surg Pathol 1992;16:975-981.
6.
de Nunzio C, Kramer G, Marberger M, et al: The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. Eur Urol 2011;60:106-117.
7.
Gandaglia G, Briganti A, Gontero P, Mondaini N, Novara G, Salonia A, Sciarra A, Montorsi F: The role of chronic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int 2013;112:432-441.
8.
Krieger JN, Nyberg L Jr, Nickel JC: NIH consensus definition and classification of prostatitis. JAMA 1999;282:263-267.
9.
Roobol MJ, Schroder FH, Hugosson J, Jones JS, Kattan MW, Klein EA, et al: Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group. World J Urol 2012;30:149-155.
10.
Al-Azab R, Toi A, Lockwood G, Kulkarni GS, Fleshner N: Prostate volume is strongest predictor of cancer diagnosis at transrectal ultrasound-guided prostate biopsy with prostate-specific antigen values between 2.0 and 9.0 ng/ml. Urology 2007;69:103-107.
11.
Gerstenbluth RE, Seftel AD, MacLennan GT, et al: Distribution of chronic prostatitis in radical prostatectomy specimens with up-regulation of bcl-2 in areas of inflammation. J Urol 2002;167:2267-2270.
12.
Irani J, Goujon JM, Ragni E, et al: High-grade inflammation in prostate as a prognostic factor for biochemical recurrence after radical prostatectomy. Pathologist Multi Center Study Group. Urology 1999;54:467-472.
13.
Karakiewicz PI, Benayoun S, Begin LR, et al: Chronic inflammation is negatively associated with prostate cancer and high-grade prostatic intraepithelial neoplasia on needle biopsy. Int J Clin Pract 2007;61:425-430.
14.
Zhang W, Sesterhenn IA, Connelly RR, Mostofi FK, Moul JW: Inflammatory infiltrate (prostatitis) in whole mounted radical prostatectomy specimens from black and white patients is not an etiology for radical difference in prostate specific antigen. J Urol 2000;163:131-136.
15.
Roberts RO, Bergstralh EJ, Bass SE, Lieber M, Jacobsen SJ: Prostatitis as a risk factor for prostate cancer. Epidemiology 2004;15:93-99.
16.
Davidsson S, Fiorentino M, Andren O, et al: Inflammation, focal atrophic lesions, and prostatic intraepithelial neoplasia with respect to risk of lethal prostate cancer. Cancer Epidemiol Biomarkers Prev 2010;20:2280-2287.
17.
Engelhardt PF, Brustmann H, Seklehner S, Riedl CR: Chronic asymptomatic inflammation of the prostate type IV and carcinoma of the prostate: is there a correlation? Scand J Urol 2013;47:230-235.
18.
Thun MJ, Henley SJ, Patrono C: Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002;94:252-266.
19.
Gridley G, McLaughlin JK, Ekbom A, et al: Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 1993;85:307-311.
20.
Langman MJ, Cheng KK, Gilman EA, Lancashire RJ: Effect anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research data base. BMJ 2000;320:1462-1466.
21.
Neugut AI, Rosenberg DJ, Ahsan H, Jacobson JS, Wahid N, Hagan M: Association between coronary heart disease and cancer of the breast, prostate and colon. Cancer Epidemiol Biomarkers Prev 1998;7:869-873.
22.
Balkwill F, Mantovani A: Inflammation and cancer: back to Virchow? Lancet 2001;357:539-545.
23.
Hoekx L, Jeuris W, van Marck E, Wyndaele JJ: Elevated serum prostate specific antigen (PSA) related to asymptomatic prostatic inflammation. Acta Urol Belg 1998;66:1-2.
24.
Sindhwani P, Wilson CM: Prostatitis and serum prostate-specific antigen. Curr Urol Rep 2005;6:307-312.
25.
Hochreiter WW: The issue of elevated prostate cancer evaluation in men with elevated prostate-specific antigen and chronic prostatitis. Andrologia 2008;40:130-133.
26.
de Marzo AM, Platz EA, Epstein JI, et al: A working group classification of focal prostate atrophy lesions. Am J Surg Pathol 2006;30:1281-1291.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.